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Brucellosis is a highly contagious bacterial zoonosis that affects millions of people 
worldwide. Brucella is highly infectious, especially when aerosolized. The infection 
induces severe protracted diseases, which are both debilitating and incapacitating, 
hence, Brucella melitensis has been considered a potential biological warfare agent. In 
the battle against Brucella, it is crucial to know its chemical-structure and biochemistry-
metabolic characteristics. It is well known that Brucella, as well as many other 
intracellular bacterial pathogens, has evolved to survive and even proliferate within 
monocytes and macrophages cells. Depending on the route of entry (complement, Fc, 
lectin or fibronectin receptors), the fate of the bacteria will vary; it may even segregate 
from the endocytic route towards the endoplasmic reticulum. This intracellular “non 
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regular” behaviour of Brucella makes treatment difficult. Most antibiotics, although 
effective in vitro, do not actively pass through cellular membranes, or, once inside, may 
not reach the discrete intracellular niche where the bacteria is hidden. Therefore, 
complete eradication of the microorganisms is difficult to achieve, and the incidence of 
relapses is rather high. Taking these data into consideration, this review will evaluate 
the past, current and new trends in the control of brucellosis, paying special attention to 
the drug delivery systems as potential vectors for targeting these intracellular sites 
where the organisms are located. 
 
INTRODUCTION 
The parasitism of mononuclear phagocytes is an essential feature of diverse 
microorganisms [1]. For example, the recent recognition of Brucella spp. as facultative 
extracellular pathogens [2] emphasizes that these bacteria may have an extreme 
preference for the intracellular environment despite their ability to live outside host 
cells. This special feature may hamper the chemotherapeutic efficacy of many in vitro 
active antibiotics. In this review, we are going to consider Brucella and gentamicin 
(GEN) as the key actors of this special confrontation in order to learn lessons which 
would be applicable in other binomia pathogen-antibiotic. 
Bacteria of the genus Brucella cause debilitating zoonotic infections in humans. 
Pathogenic brucellae are found worldwide. Traditionally, four major Brucella species 
are distinguished on the basis of their virulence for humans: B. melitensis, B. abortus, 
B. suis, and, rarely, B. canis. B. melitensis is the most infectious to man (infective dose, 
1-10 (colony forming units) followed by B. suis (10,000), B. abortus (100,000), and, 
finally, B. canis (>1,000,000 in immuno-compromised people). Systemic infection can 
result in a chronic and debilitating febrile illness commonly known as Malta fever or 
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undulant fever [3]. People acquire this disease through direct contact with infected 
animals or their products. Humans may also be infected through exposure to the 
brucellae in the laboratory. What’s more, the CDC classifies B. abortus, B. melitensis 
and B. suis as "agents of mass destruction" BSL-3 organisms, due to their ability to 
infect humans through aerosol exposure.  
The mechanisms underlying the way in which Brucella is able to enter and survive 
within the host cells, such as the macrophages, are not yet clear. Within macrophages, 
Brucella appears to be so well adapted from a physiological standpoint that it is able to 
resist the harsh environmental conditions encountered. In fact, the primary basis for the 
chronicity of Brucella infections lies in the capacity of the brucellae to persist for 
prolonged periods in the phagosomal compartment of these host phagocytes. As a 
consequence, the choice of antibiotic for brucellosis treatment is based on the drug’s 
facility to enter into these cells. Some data will be introduced in this review, regarding 
the understanding of the antibiotic chemotherapy struggle against intracellular bacteria. 
Several antimicrobials, such as tetracycline, doxycycline, aminoglycosides, rifampicin, 
trimethoprim-sulfamethoxazole, quinolones, cephalosporins, chloramphenicol and 
macrolides, have been tested on laboratory animals and humans against brucellosis [4-
12]. Monotherapies have produced unsatisfactory results. A prolonged administration of 
a tetracycline-aminoglycoside combination (i.e. doxycycline 100 mg twice/day for 45 
days and streptomycin 1 g/day for 14 days or gentamicin 5-6 mg/Kg/d for 7 days) has 
proven to be the best treatment for the disease [10, 13]. However, with relapses of 3-5% 
[10], plus serious side effects due to the tetracyclines, especially in children and 
pregnant women [4-14], there is the need to press on in search of new alternatives. 
 4
Aminoglycosides are extremely active antimicrobial agents, particularly against 
bacteraemia caused by aerobic gram-negative bacilli [15]. Gentamicin, in particular, is 
an aminoglycoside with a wide spectrum of antibacterial activity and is more active in 
vitro against clinical isolates of Brucella than the more toxic streptomycin [3, 16, 17]. 
These properties make gentamicin an attractive antimicrobial candidate for the 
treatment of brucellosis. However, as a highly water-soluble drug, it penetrates cells 
poorly. This constitutes a particularly important drawback for the therapy of 
intracellular bacterial infections [18-20]. These major hurdles may be solved by the use 
of Drug Delivery Systems. These vectors have been proposed for delivering 
antimicrobial agents and targeting intracellular sites of infection, thereby helping to 
increase the therapeutic index of antimicrobials in intracellular niches [21-24]. At the 
end of this manuscript, we review the work on the development of new approaches to 
an effective pharmaceutical dosage form of gentamicin for the treatment of brucellosis. 
Liposomes and biodegradable microspheres loaded with antibiotics appear useful for 
targeting monocytes and reducing intracellular Brucella infection; these delivery 
systems should represent a promising alternative approach for the treatment of 
intracellular bacterial infections. 
 
ENTRY AND FATE OF BRUCELLA IN MACROPHAGES 
Bacteria and antibiotics must come into contact with eachother, and this obvious 
presumption is critical in the treatment of intracellular bacteria. A better understanding 
of the basis for the successful survival and replication of Brucella in the monocytic-
macrophagic cells should provide us with critical information for improving 
chemotherapeutic treatments. Thanks to the genomic sequence data [25], the expected 
ability of Brucella cells to express special strategies to adapt to the environmental 
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conditions encountered within these host cells has been confirmed. Thus, not only 
brucellae inside the macrophage are protected from the extracellular environment 
(antibodies, complement, antibiotics, etc.) but also the new physicochemical 
intracellular conditions induce strategical, structural and metabolic changes, making 
them resistant to, for instance, in vitro active antibiotics. In the same context of the 
confrontation, it should be stressed that the intracellular activity of antibiotics may also 
change. As a consequence, we should bear in mind that the final encounter between 
Brucella and the antibiotic was not expected after in vitro studies. 
Human monocytes readily internalize Brucella using different phagocytosis-promoting 
receptors, forming so-called brucellomes (Brucella phagosomes) (Figs. 1 and 2). 
However, in contrast to other intracellular pathogens, Brucella cells do not avoid the 
typical steps of acidification and phagosome-lysosome fusion. On the contrary, the 
survival of internalized Brucella depends on an acidic intraphagosomal pH. After that, 
in this acidic compartment, poor in nutrients and microaerobic, it becomes partially 
dormant. The new expressed metabolism associated with this “stationary phase” induces 
a generalized resistance to a variety of intramacrophagic stresses, including exposure to 
acidic pH and reactive oxygen intermediates [26, 27]. The pleotropic consequence is 
that it may reduce their sensitivity to other chemical agents, such as antibiotics. Finally, 
the brucellae course themselves to a new intracellular compartment that is favourable 
for survival and replication: the endoplasmic reticulum [28-33].  
 
EVENTS IN THE ENCOUNTER BETWEEN GENTAMICIN AND BRUCELLA 
Considering the antibiotic in face of Brucella cells, the first target for GEN is the outer 
membrane. The large size of GEN (above 1 nm) precludes its penetration through the 
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outer membrane by porin channels. On the contrary, its cationic nature facilitates its 
passage by a self-promoted pathway involving the disruption of Mg2+ bridges between 
adjacent lipopolysaccharide molecules [34-36] (Figs. 3 and 4). Subsequent transport 
across the inner membrane is an energy-dependent process, being inhibited or even 
blocked by divalent cations, hyperosmolarity, low pH, and anaerobiosis. Once in the 
cytoplasm, GEN binds irreversibly to the ribosomal 30S subunit, again through a 
potentially inhibitable energy-dependent process. This binding prevents the elongation 
of the polypeptide nascent chain by blocking the transfer of the peptidyl tRNA from the 
A-site to the P-site (Fig. 4) [37].  
Aminoglycosides are bactericidal antibiotics that show a high activity against Brucella 
in vitro [38, 39]). However, the above-mentioned environmental factors related to the 
physical location of Brucella, may affect the bactericidal activity of the antibiotic. Lets 
recall that the pathogen transits through the endocytic pathway, evading its fusion with 
lysosomes, reaching, finally, its replicative niche, the endoplasmic reticulum [28, 31, 
32]. This last compartment, where Brucella mostly resides, shows a neutral pH of 7.2; 
endosomes (the first niche for the pathogen after being uptaken) have pH 6; and in 
lysosomes where aminoglycosides accumulate, a pH of 5 is found [40]. 
On the other hand, studies in the intracellular traffic of GM, show that it transits 
principally to lysosomes, but 10% of the antibiotic transits through Golgi [41], then to 
endoplasmic reticulum and, finally, to cytoplasm, where it associates with 
mitochondrial membranes and the nucleus [42] (Fig. 2). Therefore, it is exposed to a 
range of pH between neutral (7.2 for cytoplasm and endoplasmic reticulum) and acid 
values (around 6 for endosomes and Golgi, 5.0 for lysosomes) [40]. Aminoglycosides 
are known to be lysosomotropic, because of their protonation state at acidic pH, but 
different aminoacid transporters have been described in lysosomal membranes [43, 44] 
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which could help antibiotic translocation to the cytoplasm and subsequently enter the 
pathogen’s compartment. These findings agree with Sandoval et al. [41, 45, 46] who 
proposed that the antibiotic would follow a retrograde traffic from Golgi to endoplasmic 
reticulum, and, after its release in cytoplasm, would bind to mitochondria and nucleus.  
At low pH, these antibiotics increase their MIC due to changes in their degree of 
ionization. Thus, an acidification from pH 7.5 to 6.5 would increase GEN´s MIC 16-
fold and at pH 5, 64-fold [47]. Under our experimental conditions, at neutral pH, 
bactericidal concentration of the GEN (0.5 μg/mL) eliminated all infective brucellae 
within 8 h. In contrast, at pH 5 and 6 it was unable to reduce bacterial counts. Lack of 
GEN activity is related to the protonation of the molecule at acidic pH [47] and since 
antibiotic enters the bacteria by active transport, factors affecting this mechanism 
(divalent cations, hiperosmolarity, anaerobiosis and acid pH) would reduce GEN 
antibacterial activity [37].  
Similarly, azithromycin is not active against Brucella, neither on animal models nor in 
vitro conditions when mimicking the intracellular ones [8, 11, 48]. It is a well known 
fact that in alkali media, the macrolides are very active, but its activity is reduced by 
between 50 and 200 times when the test is performed under acidic conditions [8]. A 
series of determinations of azithromycin were made at different pH values and it could 
be seen that at pH≤ 6.5 (close to the intraphagosomal pH) the MIC was >128 μg/ml. 
That is to say, Brucella in intracellular conditions would be resistant to azithromycin 
(>8 μg/ml) [48]. 
 
GENTAMICIN  BIODISPONIBILITY AND DRUG DELIVERY SYSTEMS 
The goal is to reach a sufficiently high concentration in the target organs to cope with 
the loss of activity caused by low pH. The intracellular concentration depends on 
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penetration, accumulation and disposition [20, 49]. However, as discussed above, GEN, 
being polar, does not pass efficiently across membranes, and therefore is taken up by 
endocytosis, which results in an exclusively lysosomal localization helped by its 
lysosomotropism. Lysosomotropic substances are weak organic bases that can pass 
through biological membranes and concentrate in the cell compartments of low pH 
values (i.e., lysosomes).  
Aminoglycosides have shown such limited intracellular activity compared to their 
strong bactericidal potential in extracellular medium [50] that they have been used in 
vitro to eliminate extracellular bacteria without compromising intracellular survival [51, 
52]. Nevertheless, some authors have observed that aminoglycosides are readily 
incorporated into phagocytes when these cells are in contact for prolonged periods [50]. 
Supporting these observations, our own experimental experience using THP-1 human 
monocytes, revealed that only a small amount of GEN is able to enter these cells and 
that ratio of the intracellular concentration of antibiotic to the extracellular one (I/E) was 
0.001 at all concentrations studied (Lecároz et al, unpublished results). The linear 
increase in intracellular accumulation of the antibiotic with extracellular concentration 
suggested that the pinnocytosis proposed for GEN entrance [53] was not a saturated 
process, even at the high concentrations studied. Previous works performed in 
macrophages using a lower concentration of antibiotic (18 µg/mL), obtained higher I/E 
ratios, between 0.3-1.0 [50] compared to our ratio (0.001). However, different cell lines, 
incubation times and antibiotic concentrations were used. Besides, the washing of cell 
monolayers to remove extracellular antibiotic, potentially underestimates antibiotic cell 
uptake since most antibiotics reemerge from the cell very rapidly during the washing 
procedure [50]. Other studies performed in fibroblasts had shown that after the 
incubation of high antibiotic concentrations (500 and 100 µg/mL) for several days, an 
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accumulation of the drug occurs with I/E ratios of 6. Therefore, very long incubation 
periods required for GEN accumulation would mean the maintenance of high 
circulating GEN concentrations. Since free GEN is rapidly eliminated showing a plasma 
half-life of 2-3 h [54], sustained drug concentrations could not be achieved.  
Therefore, in order to get in vivo sustained bactericidal concentrations, the use of “drug 
delivery systems” has been suggested. Besides, these vectors may help to drive the 
antibiotic to Brucella´s niche in the target liver and spleen organs. 
Liposome-encapsulated aminoglycosides offer possibilities for increasing the 
therapeutic index of this class of antibiotics. Liposomes with a membrane-like structure 
favour good cell interaction and their versatility in terms of structure and composition 
grant them their main advantages. Moreover, in our work, important therapeutic activity 
in experimental models of brucellosis [55, 56] have been exhibited. However, stability 
issues, both during storage and after injection, and reproducibility in terms of the 
production of a well-defined and consistent formulation, still need attention. 
Conversely, microspheres represent a more stable system and offer the advantage of 
providing controlled release of the encapsulated GEN which could minimize the need 
for multiple injections. The intracellular antibiotic efficiency of GEN-loaded 
microspheres in the context of Brucella-infected monocytes was first examined in vitro. 
Our results indicated that GM containing poly (lactide-co-glycolide) (PLGA) 50:50H 
microspheres, significantly reduced the number of intracellular bacteria [57]. However, 
the experimental conditions used were not the most appropriate to extrapolate the 
results to the human brucellosis condition, since murine monocytes and B. abortus were 
used for the infection studies. Besides, the method of preparation of the microspheres 
was based on the spray-drying technique that rendered a high degree of aggregation 
among particles [58]. Therefore, further experiments were performed with the more 
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virulent B. melitensis strain to in vitro infect THP-1 human monocytes. Furthermore, we 
developed a solvent-evaporation method to successfully encapsulate GEN in PLGA 
microparticles, avoiding hydrophobic aggregations [59]. Different co-polymers of 
PLGA were used, 502H and 75:25H being the most appropriate. The results 
demonstrated that PLGA microparticles were efficiently captured by the macrophages 
(Figs. 5 and 6), and that the GEN released from these particles was active, being able to 
exert its bactericidal effect inside the macrophagic cells.  
By transmission electron microscopy and inmunocitochemistry (gold-labelled 
antibodies against GEN) the lack of fusion between, both, microspheres and the 
pathogen’s niche (Fig. 6) was noted. However, the antibiotic released from the particles 
was observed in the cytoplasm and nucleus and also entered the vacuoles harbouring 
Brucella. Once inside the lysosomes, upon micro particle degradation [60], the 
antibiotic would be released to the cytoplasm and other intracellular compartments (see 
above) [61]. 
Regarding particle distribution in vivo, microparticles prepared using PLGA 502H or 
PLGA 75:25H were successfully delivered to the liver and spleen. Furthermore, 
microparticles of 502H and 75:25H PLGA released their content in a sustained manner. 
Pharmacokinetics parameters illustrated the markedly altered distribution of PLGA -
loaded GEN compared to the free drug, observing higher concentrations of GEN in the 
spleen and liver when it was administered loaded in microspheres. At the same time, 
undetectable concentrations were obtained in the serum samples, precluding drug 
accumulation in the kidneys. Distribution studies showed that after two weeks, only 
75:25H intact microspheres were observed in the spleen, and, in discrete quantities, in 
the liver. However, GEN was detected up to four weeks later in the liver and spleen 
after a single dose of the microsphere formulations. This long persistence is probably 
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due to the nature of the aminoglycoside. These drugs are highly stable and are not 
metabolized in the liver. Because of their polar nature, they penetrate cells very poorly, 
but, once inside, their intracellular retention in very high [24]. 
Concentrations of GEN in the liver and spleen were in the range of the in vitro MBC for 
B. melitensis (Lecároz et al., unpublished results). When BALB/c mice were chronically 
infected with the virulent strain B. melitensis and treated with the selected GEN 
containing formulations, both significantly reduced the splenic infection. Results also 
indicated that the treatment with free GEN was ineffective, in agreement with the 
undetectable levels of GEN found in the liver and spleen.  
The data reviewed here support the use of drug delivery systems as an alternative 
therapeutic approach for the treatment of Brucella infections.  
 
CONCLUDING REMARKS 
Treatment of intracellular bacterial infection remains both a medical and economic 
challenge. Brucellae, which thrive in macrophages, are more protected against many 
antibiotics. This explains why Brucella cells are not only harmful for the host but may 
also constitute a reservoir for recurrence and reinfection. 
Gaining a better understanding of the basis for the successful survival and replication of 
the brucellae in the host cell should provide us with critical information that can be used 
for designing and improving better chemotherapeutic strategies against brucellosis. 
Because of their strong antibacterial properties, aminoglycosides remain useful for the 
treatment of serious infections, but drug monitoring has to be strict to preserve 
antibacterial activity while avoiding toxicity as far as possible. A drug delivery system 
that helps to increase the therapeutic index of the aminoglycosides by increasing the 
concentration of the drug at the site of infection and/or reducing the nephro- and 
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ototoxicity would attract considerable interest. Liposomal and microparticle 
encapsulation of aminoglycosides provide relatively high GM entrapment efficiencies 
and efficient interaction with monocyte-macrophages; key achievements compared with 
current therapies against Brucella. 
Finally, in the battle against bacteria, it is vital to know your enemy. As a consequence, 
a key point that should be stressed from its intracellular habitat, is that Brucella is 
highly variable when comparing it with its structure in extracellular (in vitro) 
environments. Therefore, when testing new drugs, it is always necessary to study its in 
vitro behaviour mimicking in vivo conditions. All these data, together with 
pharmacokinetics and pharmacodynamics (in animal and in cell) of the administered 
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